Sino Biopharmaceutical Limited (Sino Biopharm) reported to the Hong Kong Stock Exchange on 27 March 2026 that it bought back 5.35 million ordinary shares on-market the same day.
The repurchases were executed within a price range of HK$5.85 to HK$5.89 per share, translating into a volume-weighted average cost of HK$5.8762. Aggregate consideration amounted to HK$31.44 million. All repurchased shares are intended for cancellation and will not be held as treasury shares.
The shares bought back represent approximately 0.03% of Sino Biopharm’s existing issued share base of 18.76 billion shares. Because the cancellation had not been completed by the reporting date, the company’s issued share capital formally remained unchanged at 18.76 billion shares.
The transaction was conducted under the general mandate granted on 10 June 2025, which authorises Sino Biopharm to repurchase up to 1.88 billion shares. Following this exercise, only 5.35 million shares—equivalent to 0.03% of the mandate limit—have been utilised, leaving substantial headroom for further buybacks if the company chooses.
Under Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 26 April 2026, 30 days after the latest repurchase.
All figures and information are sourced solely from Sino Biopharm’s Next Day Disclosure Return dated 27 March 2026.
Comments